Clinical Trial: A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With <

Brief Summary: To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months

Original Primary Outcome: Same as current

Current Secondary Outcome: MK0217 will be safely tolerated

Original Secondary Outcome: Same as current

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: May 30, 2007
Date Started: October 2001
Date Completion:
Last Updated: March 3, 2017
Last Verified: March 2017